Biocon Biologics Inc. is a global leader in biosimilars, advancing affordable biologic therapies for diabetes, cancer, and autoimmune diseases across 120+ countries.
Import Shipments
Distribution Centers
Annual Revenue
Founded
Biocon Biologics has recently focused on expanding its biosimilar portfolio, securing regulatory approvals, and strengthening its global distribution capabilities.
FDA approval of Kirsty™, the first interchangeable rapid-acting insulin aspart in the U.S.
Strategic efforts to expand market presence and reach new customer segments.
Implementation of advanced technologies to improve service delivery and customer experience.
Biocon Biologics Inc. is a fully integrated global biosimilars company focused on making life-changing therapies accessible and affordable. Its portfolio includes over 20 biosimilars, with 9 commercialized in major markets such as the U.S., Europe, Australia, Canada, and Japan. The company has supplied more than 9.2 billion doses of insulin globally since 2004 and benefits over 5.8 million patients annually. Biocon Biologics is recognized for its pioneering R&D, robust manufacturing capabilities, and commitment to ESG principles.
